Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-Current Deffered Revenue: 2019-2025

Historic Non-Current Deffered Revenue for Kymera Therapeutics (KYMR) over the last 3 years, with Sep 2025 value amounting to $14.0 million.

  • Kymera Therapeutics' Non-Current Deffered Revenue was N/A to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year change of. This contributed to the annual value of $16.8 million for FY2023, which is 40.11% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Non-Current Deffered Revenue stood at $14.0 million, which was up 337.66% from $3.2 million recorded in Q2 2024.
  • Kymera Therapeutics' 5-year Non-Current Deffered Revenue high stood at $64.7 million for Q1 2021, and its period low was $3.2 million during Q2 2024.
  • For the 3-year period, Kymera Therapeutics' Non-Current Deffered Revenue averaged around $17.1 million, with its median value being $16.8 million (2023).
  • Data for Kymera Therapeutics' Non-Current Deffered Revenue shows a maximum YoY crashed of 84.38% (in 2024) over the last 5 years.
  • Over the past 5 years, Kymera Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $39.3 million in 2021, then declined by 28.74% to $28.0 million in 2022, then crashed by 40.11% to $16.8 million in 2023, then plummeted by 84.38% to $3.2 million in 2024, then reached $14.0 million in 2025.
  • Its Non-Current Deffered Revenue stands at $14.0 million for Q3 2025, versus $3.2 million for Q2 2024 and $23.8 million for Q1 2024.